Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) ...
Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered ...
Eli Lilly partners with telehealth company Ro to distribute discounted Zepbound vials at $399/month, while competitor Novo ...
"Wanted" posters of healthcare CEOs were put up in New York City in the wake of the killing of UnitedHealthcare CEO Brian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback